Magaldrate

${\displaystyle {\ce {[Al^{3+}][Mg^{2+}]2[HO^{-}]7[H2O]))}$
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a682683
Pregnancy category	C
Routes of administration	Oral
ATC code	A02AD02 (WHO) A02AF01 (WHO) (combination with antiflatulents)
Legal status
Legal status	In general: Over-the-counter (OTC)
Pharmacokinetic data
Bioavailability	Negligible
Metabolism	Nil
Excretion	Fecal and renal
Identifiers
IUPAC name Magnesium aluminate monohydrate
CAS Number	74978-16-8 Y
PubChem CID	6336542
ChemSpider	4891688 Y
UNII	6V88E24N5T
CompTox Dashboard (EPA)	DTXSID00157184
ECHA InfoCard	100.115.465
Chemical and physical data
Formula	AlMg2(OH)7·H2O
Molar mass	212.66 g/mol
InChI InChI=1S/Al.Mg.2H2O/h;;2*1H2/p-1 Y Key:SXSTVPXRZQQBKQ-UHFFFAOYSA-M Y
(verify)

Magaldrate (INN) is a common antacid drug that is used for the treatment of duodenal and gastric ulcers, esophagitis from gastroesophageal reflux.

Development

Magaldrat was first synthesized by the German chemist Gunther Hallmann and patented on February 2, 1960, by Byk Gulden Lomberg Chemische Fabrik (Germany).^[1] In 1983, the active substance was registered as the original drug Riopan.^[2]

Available forms

Magaldrate is available in the form of oral suspension or tablets.

Pharmacology

Magaldrate is a hydroxymagnesium aluminate complex that is converted rapidly by gastric acid into Mg(OH)₂ and Al(OH)₃, which are absorbed poorly and thus provide a sustained antacid effect.^[3]

Interactions and adverse reactions

Magaldrate may negatively influence drugs like tetracyclines, benzodiazepines, and indomethacin. High doses or prolonged usage may lead to an increment of defecation and a reduction in feces consistence. In some cases it can alter the functionality of the gastrointestinal tract, occasionally provoking constipation or diarrhea.